Sep 18 |
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
|
Sep 14 |
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
|
Sep 10 |
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
|
Sep 9 |
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
|
Sep 5 |
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely
|
Aug 15 |
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
|
Aug 13 |
Acrivon Therapeutics GAAP EPS of -$0.52
|
Aug 13 |
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
|
Jun 21 |
Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?
|
Jun 13 |
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
|